Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles The Journal of Pediatrics Year : 2020

Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation

Hélène Savel
  • Function : Author
Vincent Barlogis
Rodolphe Thiébaut

Abstract

Objective: To describe 4 subgroups of pediatric patients treated with splenectomy, hydroxychloroquine, azathioprine, or rituximab as the first-option, second-line treatment for chronic immune thrombocytopenia. Study design: Selection of patients with chronic immune thrombocytopenia from the French national prospective cohort of pediatric autoimmune cytopenia OBS'CEREVANCE and VIGICAIRE study, treated by splenectomy, hydroxychloroquine, azathioprine, or rituximab as a first second-line treatment. Results: For 137 patients, treated between 1989 and 2016, the median follow-up after diagnosis and after treatment initiation was 8.5 (2.8-26.4) years and 4.7 (1.1-25.1) years, respectively. Median age at diagnosis and at initiation of treatment were 9 (0.7; 16) and 12 (2; 18.1) years, respectively without significant difference between subgroups. For the whole cohort, 24-month event-free survival was 62% (95% CI 55; 71). It was 85% (95% CI 77; 95) for the 56 patients treated with splenectomy, 60% (95% CI 44; 84) for the 23 patients treated with rituximab, 46% (95% CI 30; 71) for the 24 patients treated with azathioprine, and 37% (95% CI 24; 59) for the 34 patients treated with hydroxychloroquine (log-rank P < .0001). For the splenectomy subgroup, being older than 10 years at splenectomy tended to improve event-free survival (P = .05). Female teenagers with antinuclear antibody positivity benefited from hydroxychloroquine therapy. Conclusions: This national study, limiting pitfalls in the analysis of the effects of second-line therapies, showed that splenectomy remains the treatment associated with the better response at 24 months.
Fichier principal
Vignette du fichier
S0022347620315006.pdf (505.77 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03481515 , version 1 (24-04-2023)

Licence

Identifiers

Cite

Stéphane Ducassou, Helder Fernandes, Hélène Savel, Yves Bertrand, Thierry Leblanc, et al.. Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. The Journal of Pediatrics, 2020, 231, pp.223-230. ⟨10.1016/j.jpeds.2020.12.018⟩. ⟨hal-03481515⟩
28 View
26 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More